Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASCO 2024 Breast Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Dr Sara Tolaney | Moderator: Professor Giuseppe Curigliano & Dr Erika Hamilton
21 June | 08:00–10:30 CDT/ 14:00–16:30 BST/ 15:00–17:30 CEST


Draft Agenda

(subject to change)

Timings are in CDT

08:00–08:15 | Session 1: Latest in ctDNA and patient stratification
  • Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC) – #LBA507: TBC
  • Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial – #512: TBC
  • Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER) – #505: Kevin Kalinsky
08:15–08:35 | Panel discussion
08:35–09:05 | Session 2: Advances with antibody-drug conjugates
  • SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer – #LBA1004: Ana Garrido-Castro
  • TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2 – #1021: Nadine Tung
  • A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy – #LBA500: Pierfranco Conte
  • Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202 –#1005Antonio Giordano
  • DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC – #1009: TBC
  • Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial – #LBA509TBC
09:05–09:25 | Panel discussion
09:25–09:40 | Session 3: Novel endocrine therapy combination approaches
  • First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses – #1003: TBC
  • Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer – #1008: Eva Ciruelos
  • Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial – #LBA1001: Kevin Kalinsky
09:40–10:00 | Panel discussion
10:00 | End of webinar


This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.